Managing central nervous system spread of lung cancer: the state of the art
DCC Tsui, DR Camidge, CG Rusthoven - Journal of Clinical Oncology, 2022 - ascopubs.org
… lung cancer care. In this article, we review the management and recent advances in the
treatment of lung cancer with spread to the CNS… Discordant CNS and extra CNS responses were …
treatment of lung cancer with spread to the CNS… Discordant CNS and extra CNS responses were …
CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives
LA Berger, H Riesenberg, C Bokemeyer… - Lung Cancer, 2013 - Elsevier
… Remarkably, in this population, which was probably enriched for patients with activating
EGFR mutations (Asian ethnicity, mostly never-smokers, adenocarcinomas), the CNS response …
EGFR mutations (Asian ethnicity, mostly never-smokers, adenocarcinomas), the CNS response …
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer
SM Gadgeel, AT Shaw, R Govindan… - Journal of Clinical …, 2016 - ascopubs.org
… CNS DCR (CDCR) was defined as the percentage of patients who had a best overall CNS
response … first observation of a CNS response until the first observation of CNS progression or …
response … first observation of a CNS response until the first observation of CNS progression or …
An update on the treatment of CNS metastases in small cell lung cancer
WA Castrucci, JPS Knisely - The Cancer Journal, 2008 - journals.lww.com
… Prophylactic cranial irradiation is indicated following complete response to induction
therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom …
therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom …
[HTML][HTML] Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against …
P Economopoulou, G Mountzios - Translational lung cancer …, 2016 - ncbi.nlm.nih.gov
… chemotherapy for BM, with intracranial response rates (RR) comparable to systemic RR,
warranting further research on the role of chemotherapy in CNS disease from NSCLC (7-12). …
warranting further research on the role of chemotherapy in CNS disease from NSCLC (7-12). …
[HTML][HTML] Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX …
… cell lung cancer (NSCLC) is characterized by a high prevalence of central nervous system
(CNS… Although CNS responses are well documented with ceritinib, these differences, together …
(CNS… Although CNS responses are well documented with ceritinib, these differences, together …
CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: data from a randomized phase III trial (AURA3)
YL Wu, MJ Ahn, MC Garassino, JY Han… - Journal of Clinical …, 2018 - ascopubs.org
… was CNS objective response rate (ORR). … CNS tumor shrinkage. Additional analyses
included the effect of prior radiotherapy on CNS response and a competing risk analysis of CNS …
included the effect of prior radiotherapy on CNS response and a competing risk analysis of CNS …
[HTML][HTML] Advances in the management of central nervous system metastases in non-small cell lung cancer
A D'Aiello, E Miao, H Cheng - Cancers, 2023 - mdpi.com
… CNS response lasting in the range of 9–12 months only (Table 1). In addition, while there
is limited data on toxicities from combined approaches of SRS and TKIs, there is the potential …
is limited data on toxicities from combined approaches of SRS and TKIs, there is the potential …
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or …
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
… central nervous system (CNS) and elicit responses in patients with brain metastases (BM)
from non–small cell lung cancer (… impact on the development and control of CNS metastases. …
from non–small cell lung cancer (… impact on the development and control of CNS metastases. …
Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC).
DM Jackman, SL Mach, JC Heng, MS Rabin… - 2013 - ascopubs.org
… The overall CNS response rate was 10% (1/10); 2 others achieved CNS stability. Median
overall survival was 1.7 months (range 0.6 – 7.0). There was no clear correlation between …
overall survival was 1.7 months (range 0.6 – 7.0). There was no clear correlation between …
相关搜索
- cell lung cancer
- initial treatment for patients lung cancers
- non-small cell lung cancer egfr tki
- small cell lung cancer cns efficacy
- non-small cell lung cancer brain metastases
- small cell lung cancer cns metastases
- egfr mutant lung cancers
- pulse dose lung cancers
- small cell lung cancer lymphoma kinase
- cell lung cancer patients brain metastases
- non-small cell lung cancer radiation therapy
- non-small cell lung cancer patients
- small cell lung cancer cns response
- non-small cell lung cancer nsclc